Visken

Atrial Fibrillation, Depression, prophylaxis of Angina pectoris + 2 more

Treatment

3 FDA approvals

20 Active Studies for Visken

What is Visken

Pindolol

The Generic name of this drug

Treatment Summary

Pindolol is a drug used to treat high blood pressure. It was first discovered to have a positive effect on heart rhythm problems, and further research showed that it could also be used to treat hypertension. The FDA approved Pindolol in 1982.

Visken

is the brand name

Visken Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Visken

Pindolol

1982

24

Approved as Treatment by the FDA

Pindolol, otherwise called Visken, is approved by the FDA for 3 uses like Hypertensive disease and prophylaxis of Angina pectoris .

Hypertensive disease

Used in combination with Hydrochlorothiazide / Losartan to help manage High Blood Pressure (Hypertension)

prophylaxis of Angina pectoris

Chest Pain

Effectiveness

How Visken Affects Patients

Pindolol is a type of drug used to treat high blood pressure and prevent angina. It must be taken twice a day and is safe for most people in doses ranging from 10-60 mg/day. However, patients should be aware of the potential risks such as heart failure, worsening heart disease if suddenly stopped, breathing difficulties, hiding signs of low blood sugar in diabetics, and hiding signs of an overactive thyroid.

How Visken works in the body

Pindolol is a type of medication that works to reduce heart rate and blood pressure. It works by blocking beta-1 and beta-2 adrenergic receptors. This prevents the release of a hormone called renin, which helps regulate blood pressure. It also stops the body from releasing angiotensin II and aldosterone, which are involved in vasoconstriction and water retention. Lastly, it inhibits cAMP-dependant kinase A, which decreases the amount of calcium in cells and relaxes smooth muscle, resulting in vasodilation.

When to interrupt dosage

The measure of Visken is contingent upon the determined disorder, including Hypertensive disease, Depression and prophylaxis of Angina pectoris. The amount of dosage modifies based on the style of delivery (e.g. Tablet - Oral or Tablet) noted in the table below.

Condition

Dosage

Administration

Chest Pain

, 10.0 mg, 15.0 mg, 5.0 mg

, Oral, Tablet - Oral, Tablet

Atrial Fibrillation

, 10.0 mg, 15.0 mg, 5.0 mg

, Oral, Tablet - Oral, Tablet

Depression

, 10.0 mg, 15.0 mg, 5.0 mg

, Oral, Tablet - Oral, Tablet

prophylaxis of Angina pectoris

, 10.0 mg, 15.0 mg, 5.0 mg

, Oral, Tablet - Oral, Tablet

Hypertensive disease

, 10.0 mg, 15.0 mg, 5.0 mg

, Oral, Tablet - Oral, Tablet

Warnings

Visken Contraindications

Condition

Risk Level

Notes

Shock, Cardiogenic

Do Not Combine

Atrioventricular Block

Do Not Combine

severe bradycardia

Do Not Combine

Heart Failure

Do Not Combine

Asthma

Do Not Combine

Heart Block

Do Not Combine

There are 20 known major drug interactions with Visken.

Common Visken Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Pindolol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Pindolol.

Abediterol

Major

Pindolol may decrease the bronchodilatory activities of Abediterol.

Adrafinil

Major

The therapeutic efficacy of Adrafinil can be decreased when used in combination with Pindolol.

Agrostis gigantea pollen

Major

The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Pindolol.

Visken Toxicity & Overdose Risk

An overdose of this drug may cause a slow heart rate, heart failure, low blood pressure, and difficulty breathing. Treatment for an overdose should involve addressing the symptoms and providing supportive care.

image of a doctor in a lab doing drug, clinical research

Visken Novel Uses: Which Conditions Have a Clinical Trial Featuring Visken?

Presently, 788 studies are underway to determine the potential of Visken in providing relief from Depression, Atrial Fibrillation and Hypertensive disease.

Condition

Clinical Trials

Trial Phases

prophylaxis of Angina pectoris

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Atrial Fibrillation

94 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Chest Pain

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Visken Reviews: What are patients saying about Visken?

2

Patient Review

12/23/2012

Visken for High Blood Pressure

I felt really tired after taking this medication, and it also made me more anxious. It was hard to catch my breath, and I just overall didn't feel like myself.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about visken

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is ecotrin pills used for?

"Ecotrin is a medication that is approved by the FDA to treat pain, reduce inflammation, and fever. It may also be used to prevent or treat people who have had a heart attack, stroke, or angina."

Answered by AI

Is there a generic for pindolol?

"If you are looking for a cheaper option for your medication, you may want to consider the generic version of pindolol."

Answered by AI

What is propranolol prescribed for?

"Propranolol is a type of beta blocker, a group of medicines used to treat heart problems, anxiety, and migraines."

Answered by AI

What is Visken used for?

"Visken is a prescription medication that is used to help manage the symptoms associated with high blood pressure. It may be used on its own or in combination with other medications. Visken belongs to a class of drugs known as beta blockers and has intrinsic sympathomimetic activity."

Answered by AI

Clinical Trials for Visken

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Visken clinical trials?

We made a collection of clinical trials featuring Visken, we think they might fit your search criteria.
Go to Trials
Image of University of South Florida in Tampa, United States.

Web-Based Program for Parenting Stress

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to evaluate the feasibility, usability, and preliminary benefits of implementing ACT Together for parents of children with disabilities in pediatric outpatient clinics. ACT Together includes six self-paced, web-based modules and brief weekly one-on-one coaching sessions led by a trained occupational therapist. The program is based on acceptance and commitment therapy (ACT), which teaches practical skills to help people handle stress and difficult thoughts or feelings while taking steps toward what matters to them. The main questions this study aims to answer are: * Can parents and occupational therapists complete the study activities as planned (e.g., module completion, coaching sessions, and surveys)? * Is the program usable and acceptable/appropriate/feasible to implement in this setting? * Do parents show improvements in mental health and coping-related outcomes after participating in the program? * What are the experiences and perspectives of parents and therapists regarding the program? Parents as participants will: * Complete six self-paced web-based modules and brief weekly individual coaching sessions with a trained occupational therapist. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experiences and perspectives on the program. Occupational therapists as participants will: * Complete therapist training materials and deliver brief individual coaching sessions to parent participants, including completing a post-session checklist. * Complete brief online questionnaires before starting and after delivering the program. * Take part in one online interview about their experiences and perspectives on the program.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han, PhD

Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Have you considered Visken clinical trials?

We made a collection of clinical trials featuring Visken, we think they might fit your search criteria.
Go to Trials
Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Visken clinical trials?

We made a collection of clinical trials featuring Visken, we think they might fit your search criteria.
Go to Trials